CN1704100A - Chinese compound medicinal preparation for treating asthma and method for preparing the same - Google Patents
Chinese compound medicinal preparation for treating asthma and method for preparing the same Download PDFInfo
- Publication number
- CN1704100A CN1704100A CN 200410042620 CN200410042620A CN1704100A CN 1704100 A CN1704100 A CN 1704100A CN 200410042620 CN200410042620 CN 200410042620 CN 200410042620 A CN200410042620 A CN 200410042620A CN 1704100 A CN1704100 A CN 1704100A
- Authority
- CN
- China
- Prior art keywords
- add
- ethanol
- drying
- hour
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000006673 asthma Diseases 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 238000000034 method Methods 0.000 title claims description 12
- 150000001875 compounds Chemical class 0.000 title abstract description 4
- 239000002994 raw material Substances 0.000 claims abstract description 7
- 235000004347 Perilla Nutrition 0.000 claims abstract description 4
- 241001522129 Pinellia Species 0.000 claims abstract description 4
- 244000124853 Perilla frutescens Species 0.000 claims abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 48
- 239000003814 drug Substances 0.000 claims description 40
- 239000008187 granular material Substances 0.000 claims description 28
- 210000000582 semen Anatomy 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 241000628997 Flos Species 0.000 claims description 12
- 241000218628 Ginkgo Species 0.000 claims description 12
- 235000011201 Ginkgo Nutrition 0.000 claims description 12
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 12
- 238000001035 drying Methods 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 8
- 238000001694 spray drying Methods 0.000 claims description 7
- 239000012141 concentrate Substances 0.000 claims description 6
- 230000006837 decompression Effects 0.000 claims description 6
- 238000004064 recycling Methods 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 238000012856 packing Methods 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 4
- 238000005516 engineering process Methods 0.000 claims description 4
- 238000002481 ethanol extraction Methods 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 4
- 239000000796 flavoring agent Substances 0.000 claims description 4
- 235000019634 flavors Nutrition 0.000 claims description 4
- 229940023488 pill Drugs 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- -1 suspensoid Substances 0.000 claims description 4
- 238000012546 transfer Methods 0.000 claims description 4
- 239000004375 Dextrin Substances 0.000 claims description 3
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 241000218671 Ephedra Species 0.000 claims description 3
- 241000202807 Glycyrrhiza Species 0.000 claims description 3
- 102000011759 adducin Human genes 0.000 claims description 3
- 108010076723 adducin Proteins 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 238000004321 preservation Methods 0.000 claims description 3
- 238000011084 recovery Methods 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 2
- 229940046011 buccal tablet Drugs 0.000 claims description 2
- 239000006189 buccal tablet Substances 0.000 claims description 2
- 239000007919 dispersible tablet Substances 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 239000007903 gelatin capsule Substances 0.000 claims description 2
- 238000000643 oven drying Methods 0.000 claims description 2
- 239000008188 pellet Substances 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000001291 vacuum drying Methods 0.000 claims description 2
- 241001465251 Ephedra sinica Species 0.000 abstract 1
- 244000194101 Ginkgo biloba Species 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 235000017443 Hedysarum boreale Nutrition 0.000 abstract 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 abstract 1
- 240000000249 Morus alba Species 0.000 abstract 1
- 235000008708 Morus alba Nutrition 0.000 abstract 1
- 244000018633 Prunus armeniaca Species 0.000 abstract 1
- 235000009827 Prunus armeniaca Nutrition 0.000 abstract 1
- 240000004534 Scutellaria baicalensis Species 0.000 abstract 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 abstract 1
- 240000000377 Tussilago farfara Species 0.000 abstract 1
- 235000004869 Tussilago farfara Nutrition 0.000 abstract 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 abstract 1
- 239000009940 dingchuan tang Substances 0.000 description 21
- 206010011224 Cough Diseases 0.000 description 12
- 238000011534 incubation Methods 0.000 description 8
- 241000700199 Cavia porcellus Species 0.000 description 7
- 206010062717 Increased upper airway secretion Diseases 0.000 description 5
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 5
- 229960003556 aminophylline Drugs 0.000 description 5
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 5
- 208000026435 phlegm Diseases 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 229960004373 acetylcholine Drugs 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003172 expectorant agent Substances 0.000 description 4
- 230000003419 expectorant effect Effects 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 229940124630 bronchodilator Drugs 0.000 description 3
- 239000000812 cholinergic antagonist Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- ZHIBQGJKHVBLJJ-UHFFFAOYSA-N histamine phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.NCCC1=CNC=N1 ZHIBQGJKHVBLJJ-UHFFFAOYSA-N 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 230000002048 spasmolytic effect Effects 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000229722 Perilla <angiosperm> Species 0.000 description 2
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 229960001660 histamine phosphate Drugs 0.000 description 2
- 230000003118 histopathologic effect Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 231100001252 long-term toxicity Toxicity 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229940123251 Platelet activating factor antagonist Drugs 0.000 description 1
- 208000035992 Postmortem Changes Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 241000207929 Scutellaria Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 230000036428 airway hyperreactivity Effects 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 230000007015 preclinical effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 206010037833 rales Diseases 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 208000008203 tachypnea Diseases 0.000 description 1
- 206010043089 tachypnoea Diseases 0.000 description 1
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical class O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 1
- 239000003848 thrombocyte activating factor antagonist Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000009603 uroscopy Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
Disclosed is a compound Chinese medicinal preparation for treating asthma, which is prepared from the following raw materials, gingko, Chinese ephedra, purple perilla seed, licorice root, coltsfoot flower, bitter apricot seed, mulberry bark, baikal skullcap root and pinellia tuber.
Description
Technical field
The present invention relates to a kind of compound Chinese medicinal preparation for the treatment of asthma, serves as the Chinese patent medicine that the preparation of modern crafts method is adopted on the basis with ancient prescription " DINGCHUAN TANG " specifically, the invention still further relates to the preparation method of this medicine.
Background technology
Asthma be a kind of be the respiratory system disease of feature with the airway hyperreactivity.Both at home and abroad all based on Drug therapy, the Western medicine that is used for treating asthma at present has: the treatment of (1) corticosteroid drug: this type of medicine has antiinflammatory, suppresses immunization, past thinks that always hormone is effective treatment means of control asthma, but use repeatedly and may produce drug resistance, and may suppress hypothalamus pituitary adrenal axis function, cause osteoporosis, life-time service does harm rather than good.(2) beta-receptor agonist: the bronchial smooth muscle that can relax is the most effective bronchodilator, but because of respite symptom covered the development of bronchitis, patient symptom is increased the weight of, mortality rate raises on the contrary.(3) anticholinergic bronchodilator, this type of drug effect a little less than, can be used as and replenish medication night.(4) theophylline class medicine: be phosphodiesterase inhibitor, can be used as bronchodilator.(5) 17-hydroxy-11-dehydrocorticosterone-restraining agent: as ciclosporin etc.It is clinical to also have some new pharmacotherapys to be used for gradually at present, as: selectivity phosphodiesterase inhibitor, leukotriene antagonist, anti-immunoglobulin E (IgE), anti-trypsinlike enzyme, CD-4, platelet activating factor antagonist and dna immunization inocalation method etc.Though above Western medicine is to the good effect of relievining asthma, onset is rapid, relief of symptoms at once, and great majority exist temporarily relief of symptoms, and it is poor to have a toleration, and the big and expensive shortcoming of toxic and side effects can only be hung back most of patients.(China Dispensary, calendar year 2001 the 12nd is rolled up the 7th phase 431-433 page or leaf)
Motherland's medicine has huge contribution to treatment of asthma.Traditional Chinese medical theory is thought: asthma is divided into two diseases, promptly roar disease and asthma.Heavy breathing must doublely be breathed heavily, asthma is not necessarily held concurrently and roared, and in treatment, should treat respectively.Because asthma mainly links to each other with coughing, many based on relieving cough and expelling phlegm in treatment, the Chinese patent medicine of treatment cough with asthma is more at present, as Gecko Dingchuan capsule for asthma, tetrahydro-isoquinolin oral liquid etc.But the Chinese patent medicine of treatment heavy breathing disease is less, has only " exempting from the heavy breathing sheet " according to the Chinese patent medicine of the present treatment asthma of heat type disease of finding, and it is made up of 7 flavor Chinese medicines such as Semen Lepidii (Semen Descurainiae), Pericarpium Citri Reticulatae Viride, Pericarpium Citri Reticulatae, and the function eliminating the pathogens from the lung removes heap soil or fertilizer over and around the roots, the clearing away phlegm blood stasis dispelling, and promoting the circulation of QI is relievingd asthma.Be used for bronchial asthma in acute attack stage asthma of heat type expectorant stasis of blood volt lung card, symptom sees that rough expectorant gushes, and rale is as shouting paroxysm of cough and choke, the yellow stiff of expectorant etc. but be difficult to accept because of its dose big (every day 3 times, each 8) patient." DINGCHUAN TANG " recorded in bright thorough the writing " the many wonderful recipes of health preserving " opened by the Ming Dynasty, form by Semen Ginkgo, Herba Ephedrae, Fructus Perillae, Radix Glycyrrhizae, Flos Farfarae, Semen Armeniacae Amarum, Cortex Mori, Radix Scutellariae, the Rhizoma Pinelliae, the heat clearing away of function lung qi dispersing, eliminating phlegm relieving asthma, be used for affection of exogenous wind-cold, in accumulate expectorant heat, cough ant phlegm, tachypnea asthma, Chinese medical discrimination is that stage of attack " asthma of heat type ", (Reading is always profitable sought medical advice and medicine, 2003.03,21 pages).Have experiment to show, DINGCHUAN TANG has stronger cough-relieving, eliminates the phlegm, relievings asthma and antiinflammatory action (Chinese Hospitals pharmaceutical journal, 2002 the 22nd the 4th phases of volume, 202-204 page or leaf; Chinese experimental pharmacology of Chinese medical formulae magazine, 2002 the 8th the 5th phases of volume, 40-41 page or leaf).We are in the clinical practice centuries, and its curative effect obtains curing affirming of family.It is the good recipe of treatment stage of attack " asthma of heat type is breathed heavily ".But because this side is for frying in shallow oil decoction, its quality can not be controlled, and retention is low, boil medicine time-consuming, take a lot of trouble, carry inconvenience, take shortcomings such as mouthfeel difference, be unsuitable for the market demand.
Summary of the invention
To the objective of the invention is the shortcoming of above-mentioned in order overcoming " DINGCHUAN TANG " Chinese medicine name side decoction, to make things convenient for the asthma patient to take medicine, a kind of Chinese patent medicine preparation of safe and effective, quality controllable, taking convenience is provided.Another purpose provides the preparation method of said preparation.
The present invention is achieved in that the present invention writes out a prescription to form and comes from ancient prescription " DINGCHUAN TANG ", but wherein the minority raw material is adjusted according to result of study, and its component its proportioning by weight is:
Semen Ginkgo 20-70 part Herba Ephedrae 10-50 part Fructus Perillae 10-30 part
Radix Glycyrrhizae 5-20 part Flos Farfarae 10-50 part Semen Armeniacae Amarum 5-20 part
Cortex Mori 10-50 part Radix Scutellariae 5-20 part Rhizoma Pinelliae 10-50 part
The formula optimization weight ratio scope of preparation medicine of the present invention is:
Semen Ginkgo 30-60 part Herba Ephedrae 20-40 part Fructus Perillae 15-25 part
Radix Glycyrrhizae 6-15 part Flos Farfarae 20-40 part Semen Armeniacae Amarum 10-18 part
Cortex Mori 20-40 part Radix Scutellariae 10-18 part Rhizoma Pinelliae 20-40 part
The optimum weight proportioning of medicine of the present invention is:
10 parts in 20 portions of Radix Glycyrrhizaes of 30 parts of Fructus Perillaes of 50 portions of Herba Ephedraes of Semen Ginkgo
30 parts of 15 parts of Cortex Mori of 30 portions of Semen Armeniacae Amarums of Flos Farfarae
30 parts of 15 parts of Rhizoma Pinelliaes of Radix Scutellariae
The preparation method that above-mentioned each component is made medicine of the present invention is:
1. preparation technology:
(1), Herba Ephedrae is cut into segment, all the other 8 flavor medicines pulverize separately except that Folium Perillae becomes coarse powder;
(2), get Herba Ephedrae, the Rhizoma Pinelliae, Cortex Mori, Fructus Perillae, Semen Armeniacae Amarum, Radix Glycyrrhizae and decoct with water 3 times, add 1-20 times of water gaging, decocted 0.5-5.0 hour for the 1st time; Add 5-20 times of water gaging the 2nd time, decocted 0.5-4.0 hour, add 2-18 times of water, decocted 0.5-4.0 hour for the 3rd time.Merge 3 times decocting liquid, filter, concentrate, add 95% ethanol, transfer to contain alcohol and measures, cool Tibetan, place and spend the night to 40-85%, centrifugal, get supernatant and reclaim ethanol;
(3), get Semen Ginkgo, Flos Farfarae, Radix Scutellariae with 40-8 5% alcohol reflux 3 times, add 5-20 the 1st time doubly to measure ethanol extraction 0.5-5.0 hour, respectively add 5-12 the 2nd, 3 time doubly to measure ethanol, extracted 0.5-4.0 hour, filter, merge 3 times filtrate, recovery ethanol;
(4), merge above-mentioned two kinds of extracting solution, concentrate, dry, granulate, granulate, packing, promptly.
2, above-mentioned preparation technology's condition is characterized in that:
Method for concentration can be to concentrate under the normal pressure, also can be concentrating under reduced pressure, and the concentrating under reduced pressure condition is: 0.01-0.09MPA, 40-90 ℃;
Reclaiming the ethanol method can be that normal pressure reclaims, and also can be reclaim under reduced pressure, and the decompression recycling ethanol condition is: 0.01-0.07MPA, 30-80 ℃;
Drying means can be: contact drying, pneumatic conveying drying, tunnel type oven drying, vacuum drying, airpillow-dry, spray drying, lyophilization, far-infrared ray drying, microwave drying.
3, above-mentioned prescription adopts the made Chinese patent medicine of above-mentioned preparation method, it is characterized in that said medicament is the above dosage form of saying of any medicament book.
4, above-mentioned preparation process can also be made said dosage form on any medicament book after getting extractum, and they are granule, capsule, tablet, oral liquid, pill, suspensoid, drop pill, pellet, buccal tablet, soft gelatin capsule, soft capsule, dispersible tablet, solution, aerosol, spray, cataplasma, patch etc.
Show that through pharmacological evaluation beneficial effect of the present invention is as follows:
(1), an important feature of the present invention is to have the contraction that dose dependent ground suppresses isolated helical strips of guinea due to histamine phosphate and the acetylcholine, is spasmolysis significantly.
Method: get the 300-400g Cavia porcellus, the male and female dual-purpose hits its head with wooden stick and separates trachea rapidly, and make strip-spiral, be equipped with in the Magnus' bath of nutritional solution, normal contraction tension curve before the record administration adds histamine phosphate (1.67 * 10 then respectively in bath
-6G/ml) or acetylcholine (1.67 * 10
-6G/ml), record tracheal strip shrink tension curve when its tension force rises to peak, adds in this bath and respectively organizes reagent, makes its concentration reach 2.26 * 10 respectively
-4, 2.26 * 10
-3With 2.26 * 10
-2G/ml, matched group aminophylline 1.0 * 10
-3G/ml and normal saline, 3min tension curve fall after the observed and recorded administration.The tension variation of 10 tracheal strips of every group record is calculated the spasmolytic percentage rate of respectively organizing tracheal strip.And contrast between organizing, the t test.Result such as following table:
The influence of the spasmolysis of experimental isolated helical strips of guinea (X ± SD)
The I histamine phosphate
Group | Dosage g/ml | Tracheal strip number (bar) | Spasmolytic rate (%) |
NS DINGCHUAN TANG granule DINGCHUAN TANG granule DINGCHUAN TANG granule aminophylline | ? ??2.26×10 -4??2.26×10 -3??2.26×10 -2??1.0×10 -3 | ??10 ??10 ??10 ??10 ??10 | ??0 ??0 ??19.19±7.65 ??127.3±37.53 ??119.3±12.50 |
The II acetylcholine
Group | Dosage g/ml | Tracheal strip number (bar) | Spasmolytic rate (%) |
NS DINGCHUAN TANG granule DINGCHUAN TANG granule DINGCHUAN TANG granule aminophylline | ? ??2.26×10 -4??2.26×10 -3??2.26×10 -2??1.0×10 -3 | ??10 ??10 ??10 ??10 ??10 | ??0 ??0.71±0.74 ??9.00±3.63 ??39.00±17.00 ??114.2±12.13 |
(2), invention also has the preclinical effect of significant prolongation acetylcholine and histamine initiation Cavia porcellus asthma.
Method: get 50 of body weight 165-200g Cavia porcelluss, be divided into 5 groups at random, every group 10, earlier Cavia porcellus is placed in the volumetrical airtight bell glass of 4L, spray into capacity mixed liquors such as 2% acetylcholine and 0.1% histamine with constant pressure, each spraying 15S, the incubation period that the tic of panting property appears in the interior Cavia porcellus of 6min is observed in timing immediately after spraying stops, if then eliminate greater than 120 seconds persons incubation period, select 60 of eligibles, evenly be divided into 5 groups at random by body weight and incubation period, 10 every group, use DINGCHUAN TANG granule 3.5 respectively, 7.0 and 10.5g/kg, aminophylline 0.1g/kg and equal-volume water, gastric infusion is 5 days continuously, once a day.Last administration is after 1 hour, Cavia porcellus is put into airtight bell glass, spray into above-mentioned drawing with constant pressure and breathe heavily medicinal liquid after 15 seconds, observe the incubation period that occurs the tic of panting property in the animal 6min, calculating is respectively organized preclinical meansigma methods and is compared with the water group respectively, carries out the t check.Result such as following table:
To the influence of Cavia porcellus antiasthmatic effect (X ± SD)
Group | Dosage (g/kg) | Number of animals (only) | Asthma incubation period (second) |
Water group DINGCHUAN TANG granule DINGCHUAN TANG granule DINGCHUAN TANG granule aminophylline | ? ??3.5 ??7.0 ??10.5 ??0.1 | ??10 ??10 ??10 ??10 ??10 | ??79.11±14.33 ??103.20±28.01 *??121.60±20.56 **??105.90±26.23 *??234.67±115.67 ** |
Compare with the water group: * P<0.05 * * P<0.01
(3) the present invention can reduce the cough number of times of white mice in addition significantly.
Method: get 50 of 18-22 gram Kunming mouses, male and female half and half, be divided into 5 groups at random by body weight, every group 10, respectively with DINGCHUAN TANG granule 10,20,30g/kg group, ZHISOU QINGGUO HEJI 12ml/kg and water, gastric infusion is 7 days continuously, once a day, after the last administration 1 hour, put into and be full of equal amounts of S O
2Beaker in, observe cough number of times in incubation period of mouse cough and the 2min, calculate the meansigma methods of every group of mouse cough incubation period and cough number of times, and and the water group organize between contrast t check.The results are shown in following table:
To the influence of mice antitussive action (X ± SD)
Group | Dosage (g/kg) | Number of animals (only) | Incubation period (second) | Cough number of times (inferior) |
Water DINGCHUAN TANG granule DINGCHUAN TANG granule DINGCHUAN TANG granule ZHISOU QINGGUO HEJI | ? ?10 ?20 ?30 ?12(ml/kg) | ?10 ?10 ?10 ?10 ?10 | ?45.70±13.27 ?52.70±15.73 ?44.20±12.24 ?57.90±16.58 ?31.30±10.07 | ?129.10±122.41 ?89.40±13.60 **?71.70±13.78 **?69.60±18.80 **?100.80±19.59 ** |
Compare with the water group:
*P<0.01
(4) to also have an important feature be to show by toxicologic study in the present invention, this product basic security.
Acute toxicity test: the DINGCHUAN TANG granule is given the LD of mouse stomach administration
50Be 171.09g/kg, 95% the credible 143.21-204.38g/kg that is limited to.
The rat long term toxicity test is the result show: DINGCHUAN TANG granule heavy dose (72.6g/kg, be equivalent to 52.6 times of people's consumptions), long term administration (60 days) can make that rat body weight alleviates, platelet count reduction, cruor time extending, ALT, AST raise, but observed for 3 weeks after the drug withdrawal, it is normal that above-mentioned variation all recovers.The no abnormal change of histopathologic examination.Be equivalent to 26.3 times of (36.3g/kg) following dosage groups of people's consumption, above-mentioned toxicity do not occur.
Beagle dog long term toxicity test is the result show, with being equivalent to more than 8.7 times of 60kg people's consumption per day 69g/ day more than this product 10.0g/kg, long term administration (90 days), the dog food ration is reduced and lose weight, but hematological examination, blood biochemical is learned inspection, uroscopy, Electrocardioscopy and histopathologic examination does not all have obvious pathological abnormalities.And obvious ANOMALOUS VARIATIONS does not all appear in 5.0g/kg dosage group (being equivalent to 4.4 times of people's consumptions).
The specific embodiment
Embodiment 1
Take by weighing raw material by following proportioning: 30 parts of 15 parts of Rhizoma Pinelliaes of 30 parts of Radix Scutellariaes of 15 parts of Cortex Mori of 30 portions of Semen Armeniacae Amarums of 10 portions of Flos Farfaraees of 20 portions of Radix Glycyrrhizaes of 30 parts of Fructus Perillaes of 50 portions of Herba Ephedraes of Semen Ginkgo
(1), Herba Ephedrae is cut into the long segment of 1CM, all the other 8 flavor medicines pulverize separately except that Folium Perillae becomes coarse powder;
(2), get Herba Ephedrae, the Rhizoma Pinelliae, Cortex Mori, Fructus Perillae, Semen Armeniacae Amarum, Radix Glycyrrhizae and decoct with water 3 times, add 12 times of water gagings, decocted 2 hours for the 1st time; Add 10 times of water gagings the 2nd time, decocted 1 hour, add 7 times of water gagings, decocted 1 hour for the 3rd time.Merge 3 times decocting liquid, filter concentrating under reduced pressure (0.07MPA, 70 ℃), to relative density 1.02-1.07, put coldly, add 95% ethanol, transfer to contain the alcohol amount to 70%, cold preservation (below 10 ℃), place and to spend the night, centrifugal, get supernatant decompression recycling ethanol (0.04MPA, 60 ℃);
(3), get Semen Ginkgo, Flos Farfarae, Radix Scutellariae with 60% alcohol reflux 3 times, add 10 times of amount ethanol extractions 2 hours the 1st time, respectively add 7 times of amount ethanol the 2nd, 3 time, extracted 1 hour, filtration merges 3 times filtrate, decompression recycling ethanol (0.04MPA, 60 ℃);
(4), merge above-mentioned two kinds of extracting solution, concentrating under reduced pressure (0.07MPA, 60 ℃), spray drying (extractum: dextrin is 1.6: 1 for 100 ℃ of intake air temperatures, 60 ℃ of air outlet temperature), one-step palletizing, granulate, packing promptly gets granule.
Claims (10)
1, a kind of medicine for the treatment of asthma, it is characterized in that this medicine is the medicament of being made by the following weight proportion raw material: its raw material proportioning by weight is:
Semen Ginkgo 20-70 part Herba Ephedrae 10-50 part Fructus Perillae 10-30 part
Radix Glycyrrhizae 5-20 part Flos Farfarae 10-50 part Semen Armeniacae Amarum 5-20 part
Cortex Mori 10-50 part Radix Scutellariae 5-20 part Rhizoma Pinelliae 10-50 part.
2, medicine according to claim 1 is characterized in that the weight proportion of its raw material is:
Semen Ginkgo 30-60 part Herba Ephedrae 20-40 part Fructus Perillae 15-25 part
Radix Glycyrrhizae 6-15 part Flos Farfarae 20-40 part Semen Armeniacae Amarum 10-18 part
Cortex Mori 20-40 part Radix Scutellariae 10-18 part Rhizoma Pinelliae 20-40 part.
3, medicine according to claim 1 is characterized in that the weight proportion of its raw material is:
10 parts in 20 portions of Radix Glycyrrhizaes of 30 parts of Fructus Perillaes of 50 portions of Herba Ephedraes of Semen Ginkgo
30 parts of 15 parts of Cortex Mori of 30 portions of Semen Armeniacae Amarums of Flos Farfarae
30 parts of 15 parts of Rhizoma Pinelliaes of Radix Scutellariae.
4, according to the medicine of claim 1,2 or 3 described treatment asthma, it is characterized in that: the dosage form of described medicine is granule, capsule, tablet, oral liquid, pill, suspensoid, drop pill, pellet, buccal tablet, soft gelatin capsule, soft capsule, dispersible tablet, solution, aerosol, spray, cataplasma or patch.
5, treatment asthmatic medicament according to claim 4, it is characterized in that: said dosage form is a granule.
6, the preparation method of the described treatment asthmatic medicament of claim 5 is characterized in that: comprise the following steps:
(1), Herba Ephedrae is cut into segment, all the other 8 flavor medicines pulverize separately except that Folium Perillae becomes coarse powder;
(2), get Herba Ephedrae, the Rhizoma Pinelliae, Cortex Mori, Fructus Perillae, Semen Armeniacae Amarum, Radix Glycyrrhizae and decoct with water 3 times, add 1-20 times of water gaging, decocted 0.5-5.0 hour for the 1st time; Add 5-20 times of water gaging the 2nd time, decocted 0.5-4.0 hour, add 2-18 times of water, decocted 0.5-4.0 hour for the 3rd time.Merge 3 times decocting liquid, filter, concentrate, add 95% ethanol, transfer to contain alcohol and measures, cold preservation, place and spend the night to 40-85%, centrifugal, get supernatant and reclaim ethanol;
(3), get Semen Ginkgo, Flos Farfarae, Radix Scutellariae with 40-85% alcohol reflux 3 times, add 5-20 the 1st time doubly to measure ethanol extraction 0.5-5.0 hour, respectively add 5-12 the 2nd, 3 time doubly to measure ethanol, extracted 0.5-4.0 hour, filter, merge 3 times filtrate, recovery ethanol;
(4), merge above-mentioned two kinds of extracting solution, concentrate, dry, granulate, granulate, packing, promptly.
7, the preparation method of treatment asthmatic medicament according to claim 6 is characterized in that:
Described method for concentration can be to concentrate under the normal pressure, also can be concentrating under reduced pressure, and the concentrating under reduced pressure condition is: 0.01-0.09MPA, 40-90 ℃;
Described recovery ethanol method can be that normal pressure reclaims, and also can be reclaim under reduced pressure, and the decompression recycling ethanol condition is: 0.01-0.07MPA, 30-80 ℃;
Described drying means can be: contact drying, pneumatic conveying drying, tunnel type oven drying, vacuum drying, airpillow-dry, spray drying, lyophilization, far-infrared ray drying or microwave drying.
8, according to the preparation method of claim 6 or 7 described treatment asthmatic medicaments, it is characterized in that:
Said drying means is a spray drying, and the spray drying condition is: intake air temperature 80-120 ℃, and 40-70 ℃ of air outlet temperature, extractum: dextrin is 1.3-1.8: 1; One-step palletizing, granulate, packing is promptly.
9, the preparation method of treatment asthmatic medicament according to claim 8 is characterized in that: the spray drying condition is: 100 ℃ of intake air temperatures, and 60 ℃ of air outlet temperature, extractum: dextrin is 1.6: 1.
10, according to the preparation method of the medicine of the arbitrary described treatment asthma of claim 6-9, it is characterized in that preparation technology is: get Herba Ephedrae, the Rhizoma Pinelliae, Cortex Mori, Fructus Perillae, Semen Armeniacae Amarum, Radix Glycyrrhizae and decoct with water 3 times, add 12 times of water gagings, decocted 2 hours for the 1st time; Add 10 times of water gagings the 2nd time, decocted 1 hour, add 7 times of water gagings, decocted 1 hour for the 3rd time; Merge 3 times decocting liquid, filter, concentrating under reduced pressure to relative density 1.02-1.07, is put coldly, adds 95% ethanol, transfers to contain the alcohol amount to 70%, cold preservation, places and spends the night, and is centrifugal, get the supernatant decompression recycling ethanol; Get Semen Ginkgo, Flos Farfarae, Radix Scutellariae with 60% alcohol reflux 3 times, add 10 times of amount ethanol extractions 2 hours the 1st time, respectively add 7 times of amount ethanol the 2nd, 3 time, extracted 1 hour, filtration merges 3 times filtrate, decompression recycling ethanol; Merge above-mentioned two kinds of extracting solution, concentrating under reduced pressure, spray drying, one-step palletizing, granulate, packing promptly gets granule.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410042620 CN1294941C (en) | 2004-05-27 | 2004-05-27 | Chinese compound medicinal preparation for treating asthma and method for preparing the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410042620 CN1294941C (en) | 2004-05-27 | 2004-05-27 | Chinese compound medicinal preparation for treating asthma and method for preparing the same |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1704100A true CN1704100A (en) | 2005-12-07 |
CN1294941C CN1294941C (en) | 2007-01-17 |
Family
ID=35575846
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200410042620 Expired - Lifetime CN1294941C (en) | 2004-05-27 | 2004-05-27 | Chinese compound medicinal preparation for treating asthma and method for preparing the same |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1294941C (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101007058B (en) * | 2006-01-23 | 2010-05-12 | 王忆俭 | Medicinal composition for treating bronchial asthma, chronic bronchitis and emphysema |
CN101856438A (en) * | 2010-06-03 | 2010-10-13 | 成都中医药大学 | Medicinal composition for treating infant asthma and preparation method and use thereof |
WO2011003221A1 (en) * | 2009-07-09 | 2011-01-13 | 河北以岭医药研究院有限公司 | A medicine composition for treating bronchial asthma and preparative method thereof |
CN102362947A (en) * | 2011-11-14 | 2012-02-29 | 王敬祥 | Chinese medicine for treating cough |
CN102578703A (en) * | 2012-02-17 | 2012-07-18 | 张婷婷 | Alcoholic extract paste of common coltsfoot flower and preparation method and application thereof |
CN102895443A (en) * | 2012-10-13 | 2013-01-30 | 袁小芬 | Chinese medicine for treating asthma |
CN103520413A (en) * | 2013-10-02 | 2014-01-22 | 孙明照 | Chinese medicament for treating asthma |
CN103656009A (en) * | 2013-12-11 | 2014-03-26 | 山东中大药业有限公司 | Traditional Chinese medicine composition for treating phlegmdyspnea |
CN104208328A (en) * | 2014-09-28 | 2014-12-17 | 施瑞客(天津)生物技术有限公司 | Traditional Chinese medicine composition for preventing and treating infectious pleurisy of pigs and preparation method thereof |
CN108420913A (en) * | 2018-05-18 | 2018-08-21 | 大连大学 | A kind of Chinese medicine composition and preparation method thereof for treating asthma |
-
2004
- 2004-05-27 CN CN 200410042620 patent/CN1294941C/en not_active Expired - Lifetime
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101007058B (en) * | 2006-01-23 | 2010-05-12 | 王忆俭 | Medicinal composition for treating bronchial asthma, chronic bronchitis and emphysema |
KR101416453B1 (en) * | 2009-07-09 | 2014-07-08 | 허베이 이링 메디슨 리서치 인스티튜트 코오포레이션 리미티드 | A medicine composition for treating bronchial asthma and preparative method thereof |
WO2011003221A1 (en) * | 2009-07-09 | 2011-01-13 | 河北以岭医药研究院有限公司 | A medicine composition for treating bronchial asthma and preparative method thereof |
RU2519672C2 (en) * | 2009-07-09 | 2014-06-20 | Хебей Илин Медисин Рисеч Инститьют Ко., Лтд. | Traditional chinese medical composition for treating bronchial asthma and method for preparing it |
CN101856438A (en) * | 2010-06-03 | 2010-10-13 | 成都中医药大学 | Medicinal composition for treating infant asthma and preparation method and use thereof |
CN101856438B (en) * | 2010-06-03 | 2012-06-06 | 成都中医药大学 | Medicinal composition for treating infant asthma and preparation method and use thereof |
CN102362947A (en) * | 2011-11-14 | 2012-02-29 | 王敬祥 | Chinese medicine for treating cough |
CN102362947B (en) * | 2011-11-14 | 2012-12-12 | 张涛 | Chinese medicine for treating cough |
CN102578703A (en) * | 2012-02-17 | 2012-07-18 | 张婷婷 | Alcoholic extract paste of common coltsfoot flower and preparation method and application thereof |
CN102578703B (en) * | 2012-02-17 | 2014-12-17 | 张婷婷 | Alcoholic extract paste of common coltsfoot flower and preparation method and application thereof |
CN102895443A (en) * | 2012-10-13 | 2013-01-30 | 袁小芬 | Chinese medicine for treating asthma |
CN103520413A (en) * | 2013-10-02 | 2014-01-22 | 孙明照 | Chinese medicament for treating asthma |
CN103656009A (en) * | 2013-12-11 | 2014-03-26 | 山东中大药业有限公司 | Traditional Chinese medicine composition for treating phlegmdyspnea |
CN103656009B (en) * | 2013-12-11 | 2016-06-29 | 耿怀营 | A kind of Chinese medicine composition treating phlegm dyspnea |
CN104208328A (en) * | 2014-09-28 | 2014-12-17 | 施瑞客(天津)生物技术有限公司 | Traditional Chinese medicine composition for preventing and treating infectious pleurisy of pigs and preparation method thereof |
CN108420913A (en) * | 2018-05-18 | 2018-08-21 | 大连大学 | A kind of Chinese medicine composition and preparation method thereof for treating asthma |
Also Published As
Publication number | Publication date |
---|---|
CN1294941C (en) | 2007-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1176684C (en) | 'Jiwenning' for treating chicken pest and its preparing process | |
CN102406070B (en) | Feed additive made of Chinese herbal medicine and used for reducing respiratory tract diseases of piglets | |
WO2013071727A1 (en) | Anti-tumor traditional chinese medical composition | |
CN1294941C (en) | Chinese compound medicinal preparation for treating asthma and method for preparing the same | |
CN112156156A (en) | Veterinary traditional Chinese medicine antiviral oral liquid and preparation method thereof | |
CN103961614B (en) | Chinese medicine composition for treating respiratory disease and its production and use | |
CN115414435B (en) | Chinese herbal compound Ge Houdan poria cocos granule and preparation method and application thereof | |
CN1957997A (en) | Animal use compound medicament with effects of relieving the muscles and skin, clearing away heat, relieving darrhea, and relieving dysentery, and preparation method | |
CN100336528C (en) | Chinese medicinal preparation for treating high blood pressure and high blood fat | |
CN103432420B (en) | A kind of Chinese medicine composition for the treatment of diabetes and preparation method thereof and detection method | |
CN102178721A (en) | Application of fiveleaf gynostemma herb suspension and extract to preparation of drug for treating and resisting depression | |
CN104998162A (en) | Medicine for treating cough and preparing method of medicine | |
CN104398565B (en) | The preparation method of Qibanqing particle | |
CN108186957A (en) | A kind of Chinese medicine composition for treating poultry multi-pathogenesis respiratory disease and preparation method thereof | |
CN103536879B (en) | A kind of pharmaceutical composition and preparation method for the treatment of diabetes | |
CN103520684B (en) | Traditional Chinese medicine compound for reducing blood sugar | |
CN103751244B (en) | A kind of Chinese medicine oral liquid for the treatment of infectious coryza of chicken and preparation method thereof | |
CN103566349B (en) | A kind of pharmaceutical composition for the treatment of hyperglycemia hyperlipidemia | |
CN103417653B (en) | Veterinary-use compound pure Chinese herbal medicine for treating coccidium and preparation method of oral liquid of same | |
CN101658624B (en) | Traditional Chinese medicine composite for treating chronic bronchitis and preparation method thereof | |
CN101214325B (en) | Method for preparing compound 'chenxiangwei'medicine and new use thereof | |
CN1283265C (en) | Oral medicine for treating cough and asthma and its production process | |
CN101721437B (en) | Preparation method of medicine composition used for treating chronic pharyngitis | |
CN1048639C (en) | Addiction-eliminating and body resistance-strengthening capsule | |
CN115715783B (en) | Traditional Chinese medicine composition for preventing and treating white diarrhea of pigs and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CX01 | Expiry of patent term |
Granted publication date: 20070117 |
|
CX01 | Expiry of patent term |